Clinical Trial Update: A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants

View source ↗

Summary

A clinical trial evaluating the comparative effectiveness of ibrutinib in steroid-dependent/refractory chronic graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Imbruvica (ibrutinib) (ibrutinib)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Chronic Graft vs Host Disease | Status: TERMINATED